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Abstract Background Portugal is currently facing a se-
rious economic and financial crisis, which is dictating some
important changes in the health care sector. Some of these
measures may potentially influence patients’ access to
medication and consequently adherence, which will ulti-
mately impact on health status, especially in chronic pa-
tients. Aims This study aimed at providing a snapshot of
adherence in patients with chronic conditions in Portugal
between March and April 2012. Setting Community phar-
macy in Portugal. Method A cross-sectional pilot study was
undertaken, where patients were recruited via community
pharmacies to a questionnaire study evaluating the number
of prescribed and purchased drugs and, when these figures
were inconsistent, the reasons for this. Main outcome
measures Primary and secondary adherence measures.
Failing to purchase prescription items was categorized as
primary nonadherence. Secondary nonadherence was at-
tributed to purchasing prescription items, but not taking
medicines as prescribed. Results Data were collected from
375 patients. Primary nonadherence was identified in
22.8 % of patients. Regardless of the underlying condition,
the most commonly reported reason for primary non-ad-
herence was having spare medicines at home (‘‘leftovers’’),
followed by financial problems. The latter appeared to be
related to the class of medicines prescribed. Primary non-
adherence was associated with low income (\475 €/month;
p = 0.026). Secondary non-adherence, assessed by the
7-MMAS was detected in over 50 % of all patients, where
unintentional nonadherence was higher than intentional
nonadherence across all disease conditions. Conclusion
This study revealed that more than one fifth of chronic
medication users report primary nonadherence (22.8 %)
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and more than 50 % report secondary nonadherence. Data
indicates that the existence of spare medicines and financial
constraints occurred were the two most frequent reasons
cited for nonadherence (47, 6–64, 8 and 19–45.5 %, de-
pending on the major underlying condition, respectively).
Keywords Diabetes  Hyperlipidemia  Hypertension 
Medication adherence  Portugal
Impacts of findings on practice
• Community pharmacists should be aware that poten-
tially one in every five patients do not completely fill
their prescription
• For every two patients filling their prescription, one
reports nonadherent behaviour if questioned about
medication for chronic conditions
Introduction
The Portuguese Health Care System is primarily public,
where all citizens are served by a National Health Service
(PNHS), mainly financed through taxes. By contributing to
the financing of the PNHS, Portuguese citizens earn the
right to have their medicines co-paid by the PNHS, and
they pay the remainder (out-of-pocket). The level of co-
payment attributed will depend on their income, where
lower income individuals receive a higher reimbursement
for their medicines.
Portuguese society
Portugal has approximately 10.5 million inhabitants. The
basic literacy rate declared by the Central Intelligence
Agency (CIA) world book is 95.2 %; however, only 67 %
of the active population has completed basic education (i.e.
9 years) [1]. The average person earns 1028.57 €/month
(14.400 €/year) and the minimum legal salary is
475 €/month (6.650 €/year) [2]. Life expectancy at birth
has improved considerably over the past 25 years, cur-
rently reaching nearly 80 years. Perinatal and infant mor-
tality rates have been at one of the lowest points in the EU
in recent years. Mortality rates for some of the key causes
of death under the age of 65 years, such as circulatory
diseases, have decreased since 2000. However, rates of
obesity have been rapidly increasing and the overall
smoking rate has remained high [3]. The prevalence of
diabetes in Portugal has increased from 11.7 % in 2009 to
12.7 % in 2011 [4]. A large study undertaken in adults
(18–65 years old) in Portugal during 2007 reported a
prevalence of hypertension of 42.6 % [5] and as much as
47 % for hypercolesterolemia [6].
Adherence
Adherence to therapy is considered an essential part of pa-
tient care and a pre-requisite for the achievement of clinical
goals, whilst failure to adhere will lead to suboptimal health
outcomes and unnecessary increased health care spending
[7]. Adherence rates may vary depending on the illness,
medication prescribed and even health care settings, but the
literature suggests that they are usually higher among pa-
tients with acute conditions compared to those with chronic
conditions [8, 9]. In the latter, this figure is approximately
50 % for symptomatic conditions and as low as 30 % for
asymptomatic illnesses [10–12]. A recent systematic review
has reinforced this notion by demonstrating that the absence
of symptoms has a negative impact on adherence [13].
However, these extrapolations have various flaws, as previ-
ously highlighted [14]. A clear example of the limitations
involved in substantiating these generalizations is a review
on adherence to oral hypoglycemic agents that presents a
result ranging from 36 to 93 % [15].
Persistence, a specific domain of adherence which refers
to whether patients choose to continue a treatment for the
prescribed duration, is a problem across multiple chronic
conditions. It has been reported that adherence declines from
79 % in the first 3 months to 25 % after 5 years of treatment
[16]. In a Cochrane review on interventions to improve ad-
herence to lipid lowering drug regimen, it has been cited that
only ‘‘one in every four patients continue taking their
medicines long term’’ [16, 17]. Additionally, a relationship
between patient awareness of illness and adherence has been
suggested when analyzing discontinuation rates in primary
prevention, compared to secondary prevention [18]. Others
have suggested that even within the same disease condition,
the drug class of choice may influence persistence [19],
whilst it has also been suggested that the frequency of ad-
ministrations plays a determinant role in adherence regard-
less of the underlying chronic condition [20].
In a recent study by Fischer et al. [21], one of the policy
implications when looking at primary adherence was the
alarmingly high rate of nonadherence found for the three
major conditions contributing to the burden of cardiovas-
cular disease, diabetes, hypertension and hyperlipidemia.
Primary nonadherence has been defined as the absence of
acquisition of a medicine that has been prescribed [21, 22].
A study by Horne et al. evaluated the relationship be-
tween adherence and necessity beliefs and concerns where
several comparisons were made including drug classes.
This study suggests, despite the limitations of such com-
parisons, that hypertension, diabetes and cholesterol drugs
have similar relationships with adherence for both domains
assessed [23].
Several factors have been suggested to influence ad-
herence to therapy and various classifications proposed.
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While the WHO defended the use of four categories: pa-
tient-related, medication-related, condition-related and
health care team/system-related factors [24], others have
proposed a simple dichotomy between intentional and un-
intentional adherence [25, 26], where the first refers to an
active decision of the patient and the latter refers to a
passive process where the patient fails to adhere to in-
structions by mechanisms or circumstances, where he as-
sumes little control [27]. One meta-analysis on barriers to
adherence in hypertension found forgetfulness as the most
common barrier, being one example of unintentional non-
adherence [28]. Another recent systematic review which
included multiple disease conditions suggested that higher
adherence is related to increased perception of the neces-
sity of treatment and conversely with fewer concerns about
adverse effects, both examples of intentional nonadherence
[23].
Another level to these classifications may additionally
be proposed, dividing primary and secondary adherence,
where the first refers to the acquisition of medicines and the
latter to the actual medicine-taking behaviour once the
medicines have been purchased [29].
Most published studies focus on secondary adherence
but the implementation of electronic prescription has re-
cently made the focus shift to primary adherence [21].
Secondary nonadherence occurs when patients purchase
their medication but do not take it as prescribed [21, 22].
Conversely, primary adherence can be estimated by
assessing if all medicines prescribed are indeed purchased.
In Portugal, this approach is the most feasible option as
patient databases are not yet fully integrated, implying one
cannot link prescription data with sales data by using a
unique patient code. However, it is important to understand
the current prescribing regulation. These indicate each
prescription may contain a maximum of four packages.
Additionally, there is a limit of two packages per pre-
scription item. There are exceptions, which apply for in-
stance to unitary doses, such as insulin, in which case four
packages may be prescribed.
Aim of the study
This study aimed at providing a snapshot of adherence in
patients with chronic conditions in Portugal between
March and April 2012. The specific objectives were to
determine the overall adherence rate for hypertension,
diabetes and cholesterol medications; to evaluate differ-
ences between primary and secondary nonadherence; to
explore, within secondary adherence, the proportion of
intentional versus unintentional nonadherence; and, to
evaluate the most common reported reasons for
nonadherence.
Ethical approval
Ethical approval was not sought as collected information
was not personal (only demographics and pharmacy iden-
tification, the latter being optional) and identification of
participants involved was not possible (anonymity). Pa-
tients were free to decline participation. As such, the
principles of ethical research practices were followed, such
as confidentiality and anonymity. Additionally, the re-
searchers had no conflict of interests.
Methods
A cross-sectional study was undertaken in the metropolitan
area of Lisbon between March and April 2012. All phar-
macies registered with the regulatory agency were invited
to participate (n = 661). Pharmacists were instructed to
recruit all patients during 1 month that had a prescription
for at least one drug for diabetes (oral), hypertension or
hyperlipidemia.
Sample was estimated assuming the metropolitan area of
Lisbon population to be 2,821,699 inhabitants. Excluding
those aged below 15 years old, as they do not often attend
pharmacies and are not likely to be on the chronic
medication considered of interest, the population was
2,384,335 inhabitants. Assuming the prevalence of the
phenomenon to be 50 %, a confidence level of 95 % and a
sampling error of 5 %, the estimated sample size was 384
participants. It was decided that for political reasons the
maximum number of pharmacies was to be involved in
patient recruitment. Therefore all 661 pharmacies were
invited to participate. Additionally, as the study was to be
undertaken over a very short period of time (1 month), one
could not expect a high participation rate neither a high
recruitment rate from each of the participating pharmacies.
The pharmacy participation rate was assumed to be 15 %
based on previous studies [30, 31], indicating 99 pharma-
cies would participate. As such, to achieve the estimated
sample size each pharmacy would have to recruit 3.78
patients.
Patients agreeing to participate in the study filled in a
questionnaire divided into four parts:
1. Assessment of primary adherence by the pharmacist
(evaluating if all medicines prescribed had been
purchased). When collecting data on medicines pur-
chased, the overall number of packages acquired on
that occasion was considered, regardless of whether it
was the same active substance or not (this option is
explained by the way the prescriptions are filled, as
formerly explained, making this the most feasible
option);
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2. Assessment of primary adherence reported by the
patient, followed by a description of the reasons for not
purchasing all medicines prescribed whenever appro-
priate. The option to include patients reporting primary
nonadherence due to having medicines at home is
based on the fact that this may be due to several
reasons considered of interest.
3. Assessment of secondary adherence (Considering that
this scale used cannot be applied to patients taking
medicines for the first time (incident users), as it asks
questions about their medicines-related behavior in the
past, a filter variable was created to exclude incident
users; ‘‘please answer only if you have been taking
these medicines for more than a month’’); evaluating
intentional and unintentional nonadherence using an
adapted version of the 7-MMAS validated for use in
the Portuguese language [32].
4. Socio-economic and demographic characterization of
the patient (age, gender, employment situation and
income)
All data were analyzed using SPSS version 19.0 using
univariate analyses for the characterization of the sample
and of the main variables researched, and using bivariate
analysis to explore relationships between adherence pat-
terns and part 4 of the questionnaire (socio-demographic
characterization). To analyze secondary adherence data,
individual items’ scores were considered (yes = 1;
no = 0) in addition to the overall MMAS score. The latter
was calculated by summing up all individual items, where
the higher scores indicate lower adherence. The confidence
interval considered was 95 %.
Results
Data from 375 patients were obtained from 32 pharmacies
(participation rate = 4.8 %). The mean number of patients
recruited per pharmacy was 11.72 (SD = 4.191; {1–15}).
The overall sample comprised 52.1 % female, with an
average age of 66.25 years (SD = 12.854).The sample was
primarily composed of retired people (65.7 %) and 35.5 %
of the participants earned less than 475 €/month (Table 1).
Primary nonadherence
The sample comprised mostly patients prescribed with
antihypertension medicines (n = 284). Among these pa-
tients, 45.1 % were also on antihyperlipidemia medicines
(n = 128) and 32.0 % were also on oral antidiabetic
medicines (n = 91). Fifty patients were simultaneously
prescribed medicines from all three classes.
A variable was created to classify patients in terms of
primary adherence by calculating the consistency between
the number of prescribed packages and the number of
packages, as reported by the pharmacist. Data showed that,
regardless of the underlying condition, around 80 % of the
patients in each subsample were classified as primarily
adherent, when considering full agreement between the
prescribed and the purchased number of packages. The
major difference observed was for nonadherers, since hy-
pertension was the condition with the lower proportion of
patients not purchasing any medicine (Table 2).
Considering the overall sample, most patients had two
packages prescribed (n = 113; 30.7 %), followed by one
(n = 95; 25.8 %) or three (n = 68; 18.5 %). Most patients
purchased either one (n = 122; 33.2 %) or two (n = 112;
30.4 %) packages of medicine. Only 2.2 % of the sample
were nonadherent as they did not purchase any medicine
(n = 8). On average there was a difference of 0.32 between
the number prescribed and purchased (SD = 0.678;
{0–4}). Overall, 283 patients (77.1 %) were classified as
primarily adherent as they purchased all the packages
prescribed. Therefore, a considerable minority was found
to be partially nonadherent (22.9 %). Among these, the
most common feature was to purchase one package less
than the number prescribed (n = 56; 15.3 %), followed by
2 packages less (n = 23; 6.3 %), then three (n = 3; 0.8 %)
and finally four (n = 2; 0.5 %).
Bivariate analysis was used to identify factors predicting
primary adherence (Table 3). This table indicates that low
income patients were more frequently seen to adopt non-
adherent behaviours (p = 0.026), when compared with
Table 1 Demographic characteristics of sample
Characteristic Mean (SD) Min–max
Age 66.25 (12.854) 24–93
Gender (missing = 26) n %
Male 167 47.9
Female 182 52.1
Job situation (missing = 34) n %
Active 88 25.8
Unemployed 29 8.5
Retired 224 65.7
Income (missing = 37) n %
No income 17 5.0
\475 € 120 35.5
Between 475 and 999 € 100 29.6
Between 1000 and 1499 € 54 16.0
Between 1500 and 1999 € 20 5.9
Between 2000 and 2499 € 16 4.7
Over 2500 € 11 3.3
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those earning more than 475 €/month. Similarly, retired
and unemployed citizens were also more frequently in-
volved in such behaviours, when compared with active
citizens, albeit this association did not reach significance at
the 0.05 level (p = 0.074).
Reported primary adherence
When asking if they had purchased all the medicines pre-
scribed, patients’ responses indicated that exactly the same
number of hypertensive patients (n = 49) regarded them-
selves as nonadherent. Interestingly, there were two
patients with diabetes and two patients with hyperlipidemia
that did not admit to being primarily nonadherent, despite
purchasing fewer medicines than prescribed.
For those patients reporting that they did not purchase
all the medicines prescribed, the reason for that option was
assessed and varied by therapeutic group (Table 4).
Regardless of the underlying condition, the most com-
monly reported reason for primary nonadherence was ‘‘still
having medicines at home’’, which can happen because
there are variation in packaging quantities (where some last
28 days and others last 60 days), it may result from sec-
ondary nonadherence, or simply be a reflex of patient
Table 2 Estimated Primary non-adherence (difference between the number of prescribed and purchased medicines)
Diabetes Hypertension Hyperlipideamia Overall
Number of patients 133 (35.5 %) 284 (75.7 %) 182 (48.5 %) 375 (100.0 %)
Prescribed packages M (SD) {min–max} 1.83 (1.377) {1–12} 1.77 (0.870) {1–6} 1.24 (0.439) {1–3} 2.63 (1.587) {1–12}
Purchased packages M (SD) {min–max} 1.65 (1.468) {0–12} 1.57 (0.848) {0–5} 1.03 (0.520) {0–3} 2.31 (1.551) {0–12}
Full agreement between prescribed and
purchased n (%)
112 (84.2 %) 235 (82.7 %) 144 (80.0 %) 283 (77.1 %)
Nonadherent (did not purchase any) n (%) 12 (9 %) 8 (2.8 %) 21 (11.5 %) 8 (2.2 %)
Partially nonadherent n (%) 21 (15.8 %) 49 (17.3 %) 36 (19.8 %) (22.9 %)
Table 3 Relationship between
estimated primary adherence
and hypothesized predicting
factors
Independent variables Dependent variable
Adherent n (%) Non-adherent n (%) p
Gender 0.228
Female 137 (50.0) 39 (58.2)
Male 137 (50.0) 28 (41.8)
Job situation 0.074
Active citizens 74 (26.1) 14 (16.7)
Dependent citizens (retired and unemployed) 209 (73.9) 70 (83.3)
Income 0.026
No income or below 475 € 96 (36.6) 35 (51.5)
More than 475 € 166 (63.4) 33 (48.5)
Age 0.124
Young (\65 years) 131 (46.8) 26 (36.6)
Old (C65 years) 149 (53.2) 45 (63.4)
Duration of therapy with each class 0.012
Taking OAD [ 1 month
Yes 97 (98.0) 5 (14.7)
No 2 (2.0) 29 (85.3)
Taking AHT [ 1 month 0.301
Yes 191 (95.0) 66 (98.5)
No 10 (5.0) 1 (1.5)
Taking AC [ 1 month 1.000
Yes 120 (93.8) 42 (93.3)
No 8 (6.2) 3 (6.7)
OAD oral antidiabetic drugs, AHT antihypertensive drugs, AC antihyperlipidemia drugs
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dishonesty. The second most commonly reported reason
was having financial problems, which was mentioned by
45.5 % of patients on antihyperlipidemia medicines,
35.6 % of patients on antihypertensives and only by
27.8 % of patients on antidiabetic medicines.
Predictors of primary nonadherence
A statistically significant association was found between
adherence to antidiabetic medication and, both patient
gender (p = 0.042) and income (p = 0.037), where non-
adherent behaviour significantly more frequent among fe-
males and those earning below 475 €.
In hypertension, the only variable near significance with
nonadherence was income (p = 0.052), where nonadherers
earned on average less than adherers.
In patients with hyperlipidemia no variables were sig-
nificantly associated with adherence behaviour, although
differential distribution in terms of income was observed.
Secondary adherence
The 7-MMAS was used to address therapeutic group ad-
herence for patients medicated for more than 1 month.
Nearly all the patients fell into this category {(diabetes:
n = 126; 94.7 %) (hypertension: n = 257; 95.9 %) (hy-
perlipidemia: n = 162; 93.6 %)} (Table 5).
Secondary nonadherence was much higher than primary
nonadherence, as levels reached 45 %, looking at items
independently, compared to 20 % for primary nonadher-
ence. Additionally, unintentional nonadherence was con-
sistently higher than intentional nonadherence across all
disease conditions. However, some differences are worth
mentioning. Among patients with diabetes, two features
were commonly found: admitting to be careless about the
time of medicine taking and admitting to taking more
medicine because they felt worse. Conversely, there
were few patients reporting to have stopped because they
felt better. On the other hand, among patients on antihy-
perlipidemia medicines, forgetfulness and finishing the
supply of medicine were the two reasons most commonly
given.
Considering the overall score obtained on the MMAS,
no differences were found between therapeutic groups
(Median value = 1.00). However, when considering that
responding yes to any item as being sufficient for nonad-
herence classification, patients on antihyperlipidemia
medicines had slightly higher nonadherence rates, reaching
59.5 % of the responding patients (compared to 58.3 % for
patients on antidiabetic medicines and to 54.6 % for pa-
tients on antihypertensive medicines).
Discussion
More than a fifth of patients reported primary nonadher-
ence, that is, not purchasing all their prescribed medicines.
This proportion increased to 60 % when looking at specific
Table 4 Description of reported reasons for primary nonadherence by therapeutic group
Diabetes n (%) Hypertension n (%) Hyperlipidemia n (%)
Still has medicines at home 10 (47.6) 35 (64.8) 16 (48.5)
The prescription has medicines for too long time 2 (9.5) 5 (9.3) 2 (6.1)
I think the medicine does not do me well 3 (14.3) 2 (3.7) 2 (6.1)
The medicine is not needed 0 (0.0) 1 (1.9) 4 (12.1)
I have some financial problems 4 (19.0) 18 (33.3) 15 (45.5)
Other reason 4 (19.0) 6 (11.1) 2 (6.1)
Total 21 54 33
Table 5 Reported secondary adherence by underlying condition (as suggested by the therapeutic group prescribed)
7-item MMAS Diabetes n (%) Hypertension n (%) Hyperlipidaemia n (%)
Admitting to have forgotten 44 (34.9) 91 (35.4) 73 (44.8)
Admitting to be careless about time 57 (45.6) 90 (35.6) 60 (37.0)
Admitting to have stopped because felt better 11 (8.8) 37 (14.5) 31 (19.1)
Admitting to have stopped because felt worse 8 (6.3) 12 (4.7) 9 (5.6)
Admitting to have taken more because felt worse 10 (7.9) 11 (4.4) 1 (0.6)
Admitting to have stopped because did not have more medicines 33 (26.4) 74 (29.1) 56 (34.6)
Admitting to have stopped for other reason than medical indication 13 (10.4) 27 (10.6) 19 (11.8)
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medicines-taking behaviour (Fig. 1), and is consistent with
other published data [10]. The most common reason cited
for not purchasing all medicines prescribed was having
spare medicines at home. This finding is important because
it may have serious implications for the safe and effective
use of medicines. First, the storage conditions in patients’
homes are unknown, and may have consequences for the
stability of medicines, as well as the possibility of being
used after the expiry date. Secondly, although leftover
medicines may result from different sizes of packages, it
may also be a consequence of ‘‘medicines saving’’, which
is achieved by skipping doses or taking drug holidays.
Having leftovers additionally may promote medicine
sharing among family members, with potential negative
outcomes. Moreover, the prescription may have changed
over time, with slight differences in dosage, for example,
which will be undetected by patients continually consum-
ing leftover medication. Finally, the introduction of generic
medicines, although favoring cost cutting consumers, could
possibly play an important role as it may promote
therapeutic duplication without patient awareness; when
the patient uses leftover medicines, this will be out of the
pharmacist’s control, who can no longer act to promote the
safe and effective use of medicines. An important finding
was that, regardless of the underlying condition, the most
commonly reported reason for nonadherence was having
leftover medicines, a subject with little research where
most studies focus on acute treatments [33, 34].
The second most reported reason was having financial
constraints. A study undertaken 2 years previously in
Portugal indicated that approximately 25 % of patients had
failed to purchase their medicines in the preceding year for
financial reasons [35].
Similar figures were found in primary partial nonad-
herence for the analyzed therapeutic groups. The differ-
ences detected in nonadherence can be hypothesized to be
partly explained by reimbursement to the patient, as an-
tidiabetic medicines have the highest reimbursement (90 %
of the price of medicines is paid by the National Health
Service, which is publicly financed) [36]. These findings
are supported by previous work indicating a relationship
between copayment and primary adherence [37, 38].
Some interesting differences were also found between
intentional and unintentional secondary nonadherence,
which seem to have plausible explanations. The fact that
forgetfulness was more common for hyperlipidemia pa-
tients could possibly be explained by the consequences of
the condition not being perceived as significant. Addi-
tionally, in this class a high proportion reported having
stopped because they had run out of medication, consistent
with previous literature [39]. Careless behaviour was more
often reported by patients with diabetes, which seems
logical as this therapeutic class generally requires more
daily administrations in comparison with the other
therapeutic groups studied. On the other hand, a low pro-
portion of patients with diabetes stopped because they felt
better, contrasting with a higher proportion admitting to
taking more because they felt worse; these findings seem
plausible as type 2 diabetes often has symptomatic epi-
sodes that could alert patients to their lack of glycaemic
control, in addition to complications arising at later stages
of disease progression.
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This study includes data from an important patient
sample, albeit not representative of the Portuguese
population. In fact, the study was limited to the country’s
capital. However, although the study was only conducted
in an urban area, it may be assumed that these results may
not differ significantly from rural areas, as one meta-ana-
lysis suggested that the environmental setting had no im-
pact on adherence to cardiovascular and diabetes
medication [40]. The participation rate of the pharmacies
was very low, albeit in line with other national studies
undertaken in recent years, and could be attributed to
pharmacists’ low motivation to participate in research
studies [41]. Indeed, the small sample size was an impor-
tant limitation of the present study as it had an impact on
the possibilities for data analysis and control of con-
founders. In future, a larger patient sample could be
achieved by providing incentives to pharmacists for par-
ticipation, such as CPD credits. Nonetheless, the sample
achieved represented 97.7 % of the estimated.
To overcome the limitation that the pharmacy sample was
small, the demographic characteristics of the patients were
analyzed. The sample had a majority of female patients,
consistent with the work by Martins et al. [42] on pharmacy
users. The mean age was slightly higher than expected, but
still in line with published data by Costa et al. [43] on patients
with chronic conditions visiting pharmacies. Retired people
were over-represented, which may be a consequence of re-
sponder or selection bias. In future studies, one may consider
recording the date and time of patient recruitment to study
the occurrence of selection bias.
The method chosen to estimate primary adherence is not
exactly the same as the one reported by Fisher et al. [21]
and it has not been validated. The definition adopted for
this study assumes that not refilling a prescription indicates
primary nonadherence, which may not be true. The high
proportion of patients reporting having spare medicines at
home may indicate nonadherent behaviours but could also
have other explanations previously addressed, including a
potential social desirability bias. For these reasons, using
prescription data at the point of purchase may be consid-
ered to add value in comparison to studies looking at pure
prescription data, where it is impossible to account for the
nonadherers, that is, those deciding not to purchase
medication. To overcome this method’s limitation, self-
reported adherence was also considered and data were in-
ternally checked by comparing estimated and reported
primary adherence. The overall findings indicate that the
results are internally consistent and that patients are
truthful about their medicines-taking behaviour. In the near
future, it will be possible to verify the accuracy of such
explanations as most pharmacies now have the ability to
check adherence by refill data registered within their soft-
ware; however, that is not yet fully implemented.
An additional strength of the study was the simultaneous
estimation of secondary adherence. Overall self-reported
adherence was lower than could be expected for chronic
medication users. However, when exploring various forms
of nonadherence, patients admitted to having engaged in
such behaviours. Such has been reported by Villaverde-
Cabral and Silva [35], who found a low proportion of 12 %
nonadherence, rising to 30 % or more when detailing dif-
ferent forms of nonadherent behaviour. In the current pa-
per, it has been shown that unintentional nonadherence, in
comparison with intentional, confers a higher proportion,
another result in line with the aforementioned work [35].
Finally, although it should be acknowledged that per-
haps a longitudinal design would be better suited to esti-
mate the true impact of the financial and economic crisis,
the approach chosen was appropriate to develop hypotheses
in the context of an emerging situation. As such, the study
presents useful data to identify the current situation in
Portugal in the context of medicines-taking behaviour and
the reasons for nonadherence.
Conclusion
A large minority of patients taking medication for chronic
conditions reported primary nonadherence (22.8 %). The
main reason was reported to behaving spare medicines at
home. Financial constraints were more frequently cited by
patients on a low income (\475 €), who were more com-
monly found to adopt nonadherent behaviour (p = 0.026).
Secondary nonadherence was reported by more than 50 %
of the sample, mostly arising from unintentional factors.
Analysis suggests that the ability to pay for medicines is an
important factor in whether patients take their medicine as
prescribed and is worth further exploration.
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